Get the Stockscreener App
38.50
1.05%
0.35
Exelixis Inc stock is traded at $38.50, with a volume of 1.37M.
It is up +1.05% in the last 24 hours and down -1.53% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$38.15
Open:
$38.36
24h Volume:
1.37M
Relative Volume:
0.49
Market Cap:
$10.37B
Revenue:
$2.17B
Net Income/Loss:
$521.27M
P/E Ratio:
21.75
EPS:
1.77
Net Cash Flow:
$633.79M
1W Performance:
-3.65%
1M Performance:
-1.53%
6M Performance:
+9.17%
1Y Performance:
+46.97%
1-Day Range:
$37.52
$38.79
1-Week Range:
$37.52
$40.20
52-Week Range:
$26.06
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
38.51 | 10.27B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.36 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.58 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.13 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.82 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.05 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Pancreatic Endocrine Tumor Market Set to Witness Significant Growth During the Forecast Period (2025–2034) Owing to the Expected Launch of Therapies | DelveInsight - GlobeNewswire Inc.
What recovery options are there for Exelixis Inc.2025 Key Lessons & Fast Gain Stock Tips - newser.com
Chart overlay techniques for tracking Exelixis Inc.July 2025 WrapUp & AI Powered Buy/Sell Recommendations - newser.com
Real time breakdown of Exelixis Inc. stock performanceJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com
How Exelixis Inc. stock trades during market volatilityJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - newser.com
Key metrics from Exelixis Inc.’s quarterly dataJuly 2025 Review & High Conviction Investment Ideas - newser.com
Is Exelixis Inc. (EX9) stock worth buying before Fed actionDip Buying & Long-Term Capital Growth Strategies - newser.com
Historical volatility pattern of Exelixis Inc. visualized2025 Risk Factors & Weekly Setup with ROI Potential - newser.com
Is Upward Earnings Estimate Momentum Altering The Investment Case For Exelixis (EXEL)? - Yahoo
Exelixis' (NASDAQ:EXEL) Earnings Growth Rate Lags the 35% CAGR Delivered to Shareholders - 富途牛牛
Is Exelixis Inc. forming a bottoming baseJuly 2025 Drop Watch & Weekly Setup with High ROI Potential - newser.com
Order flow analysis tools used on Exelixis Inc.Stock Surge & Real-Time Market Sentiment Alerts - newser.com
Is Exelixis Inc. (EX9) stock considered safe havenMarket Activity Report & Low Risk Entry Point Guides - newser.com
Can Exelixis Inc. stock sustain market leadership2025 Key Highlights & Weekly High Return Opportunities - newser.com
What analyst consensus says on Exelixis Inc. stock2025 Stock Rankings & Expert Approved Momentum Ideas - newser.com
Advanced analytics toolkit walkthrough for Exelixis Inc.Buy Signal & Free Community Supported Trade Ideas - newser.com
Is Exelixis Inc. (EX9) stock supported by strong fundamentalsJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - sharewise.com
What does recent volatility data suggest for Exelixis Inc.Earnings Recap Report & Fast Gain Stock Trading Tips - newser.com
Will earnings trigger a reversal in Exelixis Inc.GDP Growth & Safe Entry Trade Reports - newser.com
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise.com
Exelixis, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
Exelixis Inc. stock volume spike explainedJuly 2025 EndofMonth & Free Growth Oriented Trading Recommendations - newser.com
Automated trading signals detected on Exelixis Inc.Market Growth Review & AI Driven Price Forecasts - newser.com
Pattern recognition hints at Exelixis Inc. upside2025 Trading Volume Trends & Safe Entry Zone Identification - newser.com
How Exelixis Inc. stock performs in stagflationPortfolio Return Report & Weekly High Momentum Picks - newser.com
Is this a good reentry point in Exelixis Inc.Market Movement Recap & Expert Approved Momentum Ideas - newser.com
Exelixis shuttering Pennsylvania site, laying off 130 employees - MSN
What Risks Could Derail Master Trust Limiteds Growth Story in YEARMarket Entry Points & Superior Growth Trading - earlytimes.in
Exelixis (EXEL) Rated Equalweight by Barclays Amid Cancer Drug Outlook - MSN
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Exelixis Inc Stock (EXEL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | Director |
Jun 03 '25 |
Sale |
43.09 |
7,535 |
324,683 |
358,882 |
1.24%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):